MX2023003784A - Peptido derivado de proteina de sars-cov-2 y vacuna que lo contiene. - Google Patents

Peptido derivado de proteina de sars-cov-2 y vacuna que lo contiene.

Info

Publication number
MX2023003784A
MX2023003784A MX2023003784A MX2023003784A MX2023003784A MX 2023003784 A MX2023003784 A MX 2023003784A MX 2023003784 A MX2023003784 A MX 2023003784A MX 2023003784 A MX2023003784 A MX 2023003784A MX 2023003784 A MX2023003784 A MX 2023003784A
Authority
MX
Mexico
Prior art keywords
peptide
present
cov
sars
protein
Prior art date
Application number
MX2023003784A
Other languages
English (en)
Inventor
Yusuke Nakamura
Tetsuro Hikichi
Kazuma Kiyotani
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2023003784A publication Critical patent/MX2023003784A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención provee péptidos de epítopo que se derivan de proteínas de SARS-CoV-2 y tienen la capacidad de inducir células T citotóxicas. La presente invención provee también polinucleótidos que codifican el péptido, células presentadoras de antígeno que presentan los péptidos y células T citotóxicas que hacen blanco en el péptido, y métodos de inducción de las células presentadoras de antígeno o CTL. La presente invención además provee composiciones y composiciones farmacéuticas que los contienen como ingredientes activos. Además, la presente invención provee métodos de tratamiento o prevención de enfermedades infecciosas por coronavirus, y/o supresión del agravamiento de las enfermedades infecciosas por coronavirus al usar los péptidos, polinucleótidos, células presentadoras de antígeno, células T citotóxicas o composiciones farmacéuticas de la presente invención. La presente invención también proporciona métodos para inducir una respuesta inmunitaria contra la infección por coronavirus.
MX2023003784A 2020-09-30 2021-04-30 Peptido derivado de proteina de sars-cov-2 y vacuna que lo contiene. MX2023003784A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020164630 2020-09-30
PCT/JP2021/017159 WO2022070496A1 (ja) 2020-09-30 2021-04-30 ＳＡＲＳ－ＣｏＶ－２蛋白由来ペプチドおよびそれを含むワクチン

Publications (1)

Publication Number Publication Date
MX2023003784A true MX2023003784A (es) 2023-06-22

Family

ID=80950110

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003784A MX2023003784A (es) 2020-09-30 2021-04-30 Peptido derivado de proteina de sars-cov-2 y vacuna que lo contiene.

Country Status (4)

Country Link
AU (1) AU2021351255A1 (es)
MX (1) MX2023003784A (es)
TW (1) TW202214668A (es)
WO (1) WO2022070496A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4333887A1 (en) * 2021-05-05 2024-03-13 Inovio Pharmaceuticals, Inc. Vaccines against coronavirus and methods of use
WO2024038155A1 (en) * 2022-08-17 2024-02-22 PMCR GmbH Immunization against viral infections disease(s)
WO2024038157A1 (en) * 2022-08-17 2024-02-22 PMCR GmbH Immunization against coronavirus

Also Published As

Publication number Publication date
TW202214668A (zh) 2022-04-16
WO2022070496A1 (ja) 2022-04-07
AU2021351255A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
MX2023003784A (es) Peptido derivado de proteina de sars-cov-2 y vacuna que lo contiene.
MX2022015132A (es) Vacunas combinadas a base de acidos nucleicos.
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
CA2874936A1 (en) Vaccine
US20170165321A1 (en) Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
Cooper et al. High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N12009 and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
MX351380B (es) Composiciones y metodos de vacuna de tipo ib de virus de diarrea viral de bovino.
CO2023003242A2 (es) Vacuna contra el coronavirus y procedimiento para la preparación de la misma
RU2007115549A (ru) Вакцины на основе инактивированного цельного вируса совместимого субтипа для лечения пациентов с вич-инфекцией
BR112023021654A2 (pt) Vacina contra vírus
RU2014140731A (ru) Варианты гемагглютинина и нейраминидазы гриппа
SG10201908089VA (en) Novel dosing regimens of celgosivir for the treatment of dengue
WO2015086738A2 (en) Hiv vaccine
WO2021207281A3 (en) Vaccines, adjuvants, and methods of generating an immune response
US10449245B2 (en) Method for reducing HIV-1 reservoir size using multivalent immunogen and reservoir purging agent
MX2023008049A (es) Peptido derivado de proteina de sars-cov-2 y vacuna que lo contiene.
Hsieh et al. The effect of co-administration of DNA carrying chicken interferon-γ gene on protection of chickens against infectious bursal disease by DNA-mediated vaccination
MX2022004869A (es) Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma.
MX2022008036A (es) Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv.
WO2011011725A2 (en) Use of toxoplasma and derived compositions to prevent or treat microbial infections
KR101640716B1 (ko) 면역보조제를 첨가한 스쿠티카충 백신 조성물
MX2021015643A (es) Vacuna alogénica contra el virus de inmunodeficiencia humana (vih) basada en linfocitos t para inducir la inmunidad celular y humoral.
CN113185586B (zh) SARS-CoV-2编码蛋白来源的T细胞表位多肽及其应用